European Commission approves Roche’s Tecentriq SC, the EU's first PD-(L)1 cancer immunotherapy subcutaneous injection for multiple cancer types
Posted:
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has granted marketing authorisation for Tecentriq® SC (atezolizumab), the European Union (EU)’s first PD-(L)1 cancer immunotherapy for subcutaneous (under the skin) injection.
Amid ongoing battles over alternate supplies of blockbuster weight loss drugs, Eli Lilly filed new lawsuits against four telehealth firms and their affiliates, but is using a new line of attack — the drugmaker accused two of the companies of…
Hypertension, or high blood pressure, is known to have a direct impact on heart attack and stroke risk — but a new study has revealed its surprising link to brain health.
In a large, randomized trial, researchers led by First Hospital…
Attendees
Sponsors and Exhibitors
AI In Healthcare: A Virtual Course
Contact us